Commentary

Diabetologia

, Volume 51, Issue 9, pp 1570-1573

Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?

  • D. N. SangAffiliated withSchepens Eye Research InstituteDepartment of Ophthalmology, Harvard Medical SchoolOphthalmic Consultants of Boston
  • , P. A. D’AmoreAffiliated withSchepens Eye Research InstituteDepartment of Ophthalmology, Harvard Medical SchoolPathology, Harvard Medical School Email author 

Keywords

Anti-VEGF Bevacizumab Diabetic macular oedema Diabetic retinopathy Macular oedema Neovascularisation Pegaptanib Proliferative diabetic retinopathy Ranibizumab VEGF